ATM Sequencing and Deletion/Duplication

Understand what ATM Sequencing and Deletion/Duplication signals

LOINC codes: 21624-2, 69047-9, 77202-0, 8251-1, 8266-9
Commercial laboratory assays: 1

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for ATM Sequencing and Deletion/Duplication

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

ATM Sequencing and Deletion/Duplication

Laboratory: Quest Diagnostics
Test code: 38802
Specimen: Blood
Fasting: Not stated
LOINC: 21624-2, 69047-9, 77202-0, 8251-1, 8266-9

Laboratory assay overview

This test includes sequencing and deletion/duplication analysis of the ATM gene. Individuals assigned female at birth with an ATM pathogenic variant have an elevated risk of breast cancer. Individuals with an ATM pathogenic variant have an elevated risk of pancreatic cancer.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 38802

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.